<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The aim of this study was to evaluate the possible prognostic relevance of <z:chebi fb="0" ids="17748">thymidine</z:chebi> kinase serum levels (s-TK), an indirect marker of proliferative activity, in <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>S-TK levels were monitored by means of a radioenzyme assay in 90 patients affected by <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> (22 refractory <z:hpo ids='HP_0001903'>anaemia</z:hpo>, RA; 17 RA with ring sideroblasts, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RARS</z:e>; 21 RA with blast excess, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>; 15 RAEB in transformation, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB-T</z:e>; 15 <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:mpath ids='MPATH_501'>myelomonocytic leukaemia</z:mpath>, CMMoL) </plain></SENT>
<SENT sid="2" pm="."><plain>Mean s-TK levels (U/microliter) measured at diagnosis were 11.9 +/- 12.6 for RA, 11.4 +/- 13.6 for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RARS</z:e>, 19.9 +/- 28.4 for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>, 39.6 +/- 34.3 for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB-T</z:e> and 77.7 +/- 69.7 for CMMoL (<z:mpath ids='MPATH_458'>normal</z:mpath> values &lt; 5 U/microliter) </plain></SENT>
<SENT sid="3" pm="."><plain>With the only exception of a weak relationship with <z:chebi fb="4" ids="24996">lactate</z:chebi> dehydrogenase, no correlation was found between initial s-TK values and other clinical or laboratory parameters, such as age, <z:chebi fb="34" ids="35143">haemoglobin</z:chebi>, white blood cell or platelet count, percentage of bone marrow blasts </plain></SENT>
<SENT sid="4" pm="."><plain><z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients with s-TK &gt; 38 U/microliters, a cut-off level selected by means of ROC statistical analysis, showed a significantly shorter survival than those with s-TK &lt; 38 U/microliter (8.2 v 37.4 months, respectively; P &lt; 0.0001) </plain></SENT>
<SENT sid="5" pm="."><plain>In particular, transformation in <z:hpo ids='HP_0011009'>acute</z:hpo> <z:mpath ids='MPATH_342'>myeloid leukaemia</z:mpath> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) occurred in 17/21 (81%) of patients with s-TK &gt; 38 U/microliters and 9/69 (13%) of those with lower levels at diagnosis (P &lt; 0.0001), independently of FAB subtype </plain></SENT>
<SENT sid="6" pm="."><plain>High s-TK levels were also useful to predict evolution in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> during the course of the disease in patients with <z:mpath ids='MPATH_458'>normal</z:mpath> initial values </plain></SENT>
<SENT sid="7" pm="."><plain>Multivariate analysis confirmed the independent prognostic value of s-TK on both overall survival and risk of <z:hpo ids='HP_0011009'>acute</z:hpo> transformation </plain></SENT>
<SENT sid="8" pm="."><plain>We conclude that s-TK may be an important prognostic factor in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, strongly correlated with development of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> </plain></SENT>
</text></document>